Associations of receptor for advanced glycation end products -374 T/A and Gly82 ser and peroxisome proliferator-activated receptor gamma Pro12Ala polymorphisms in Turkish coronary artery disease patients

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 2, 2012, Pages 134-137

  Aydoǧan, Hülya Yilmaz ^a   Küçükhüseyin, Özlem ^a   Tekeli, Atike ^b   Lsbir, Turgay ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE; GLYCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; SERINE;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC);

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PPAR GAMMA; RECEPTORS, IMMUNOLOGIC; TURKEY;

EID: 84857613124     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0077     Document Type: Article

References (33)

1. Balakumar P, Rose M, Singh M (2007) PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80:1-10.
2. Bierhaus A, Hoffman MA, Ziegler R, Mawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus- the AGE concept. Cardiovasc Res 37:586-600.
3. Bohlender JM, Franke S, Stein G, Wolf G (2005) AdVanced glycation end products and the kidney. Am J Physiol Renal Physiol 289:645-659.
4. Bucciarelli LG, Wendt T, Rong L, et al. (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117-1128.
5. Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287.
6. Doney AS, Fischer B, Leese G, et al. (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24:2403-2407.
7. Duval C, Chinetti G, Trottein F, et al. (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422-430.
8. Falcone C, Campo I, Emanuele E, et al. (2005) -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 354:111-116.
9. Fisman EZ, Tenenbaum A (2009) A cardiologic approach to noninsulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8:38.
10. Gerszten RE, Rosenzweig A (1998) Coronary atherosclerosis.-In: Jameson JL (ed) Principles of Molecular Medicine. Humana Press, Chicago.
11. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695.
12. Hofmann M, Yang Q, Harja E, et al. (2005) The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. Atherosclerosis 182:301-305.
13. Hofmann MA, Drury S, Hundson BI, et al. (2002) RAGE and erthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3:123-135.
14. Hudson B, Hofmann M, Bucciarelli L, et al. (2002) Glycation and diabetes: The RAGE connection. Curr Sci 83:12.
15. Hudson B, Wendt T, Bucciareli L, et al. (2005) Diabetic vascular disease: it's all RAGE: forum review. Antioxid Redox Signal 7:11-12.
16. Kucukhuseyin O, Yilmaz-Aydogan H,-Isbir CS,-Isbir T (2009) Associations of -374/A polymorphism of receptor for adVanced glycation end products (RAGE) gene in Turkish diabetic and non-diabetic patients with coronary artery disease. In Vivo 23:949-954.
17. Li J, Schmidt AM (1997) Characterization and functional analysis of the promoter of RAGE, the receptor for adVanced glycation end products. J Biol Chem 272:16498-16506.
18. Li L, Cheng LX, Nsenga R, et al. (2006) Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 29:300-304.
19. Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83:456S-460S.
20. Libby P, Plutzky J (2007) Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-a and peroxisome proliferator- activated receptor-g agonists. Am J Cardiol 99:27B-40B.
21. Matsui T, Yamagishi S, Takeuchi M, et al. (2010) Nifedipine inhibits adVanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun. 398:326-330.
22. Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res 16:1215.
23. Novelli G, Borgiani P, Giardina E, et al. (2003) Role of genetics in prevention of coronary atherosclerosis. Curr Opin Cardiol 18:368-371.
24. Pettersson-Fernholm K, Forsblom C, Hudson BI, et al. (2003) The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52:891-894.
25. Prevost G, Fajardy I, Fontaine P, et al. (1999) Human RAGE Gly82Ser dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 26:343-348.
26. Ross R (1992) The pathogenesis of atherosclerosis.-In: An HBJ International (ed) Braunwald Heart Disease A Textbook of Cardiovascular Medicine, 4th edition. Saunders, Philadelpia, pp 1106-1124.
27. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809.
28. Ruiz-Narva´ez EA, Kraft P, Campos H (2007) Ala12 variant of the peroxisome proliferatoractivated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr 86:1238-1242.
29. Simm A, Casselmann C, Schubert A, et al. (2004) Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction. Exp Gerontol 39: 407-413.
30. Singh R, Barden A, Mori T, Beilin L (2001) AdVanced glycation end products: a review. Diabetologia 44:129-146.
31. Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233-238.
32. Wendt T, Bucciarelli L, Qu W, et al. (2002) Receptor for adVanced glycation end products (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4:228-237.
33. Yan SF, Ramasamy R, Naka Y, Schmidth AM (2003) Glycation, Inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169.